#AAO22: On the heels of PhI­II launch, Au­ra de­tails sec­ond ad­min­is­tra­tion route of its oc­u­lar on­col­o­gy drug

CHICA­GO — Ahead of its fourth quar­ter piv­otal tri­al launch, Au­ra Bio­sciences de­tailed some in­ter­im da­ta from its on­go­ing Phase II tri­al of an eye can­cer drug that the biotech hopes will re­duce the need for ra­dio ther­a­pies that can blind pa­tients with oc­u­lar tu­mors.

The biotech is at­tempt­ing to keep choroidal melanoma in check by im­ped­ing tu­mor growth while al­so pre­serv­ing vi­sion. Belzu­pacap saro­talo­can con­trolled tu­mors in most pa­tients on longer treat­ment cy­cles and near­ly all pa­tients re­tained their vi­sion in an in­ter­im look at the Phase II tri­al, with a da­ta cut­off of Aug. 19, at the Amer­i­can Acad­e­my of Oph­thal­mol­o­gy con­fer­ence in the Sec­ond City.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER